Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 4, 2010, Pages 470-476

  Akiyama, Toru ^a,b   Dass, Crispin R ^a   Shinoda, Yusuke ^b   Kawano, Hirotaka ^b   Tanaka, Sakae ^b   Choong, Peter F M ^a,c  

^a St Vincent's Health ^*  (Australia)

^b UNIVERSITY OF TOKYO   (Japan)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Osteoclast; Osteosarcoma; RANK; RANKL; Tumour

Indexed keywords

ACID PHOSPHATASE; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TARTARIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BONE STRUCTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; MALE; MOUSE; NEWBORN; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOSARCOMA; PRIMARY TUMOR; SYSTEMIC THERAPY;

EID: 77952798405     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.04.0009     Document Type: Article

References (33)

1. Akiyama T et al. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway Mol Cancer Ther 2008 7 : 3461 3469.
2. Akiyama T et al. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim EMBO J 2003 22 : 6653 6664.
3. Tanaka S et al. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system Immunol Rev 2005 208 : 30 49.
4. Mundy GR Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2002 2 : 584 593.
5. Schwarz EM, Ritchlin CT Clinical development of anti-RANKL therapy Arthritis Res Ther 2007 9 1 S7.
6. Ulrich-Vinther M et al. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis J Bone Joint Surg Am 2002 84-A : 1405 1412.
7. Goater JJ et al. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis J Orthop Res 2002 20 : 169 173.
8. Montier T et al. Non-viral vectors in cystic fibrosis gene therapy: progress and challenges Trends Biotechnol 2004 22 : 586 592.
9. Lamoureux F et al. Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma Mol Cancer Ther 2008 7 : 3389 3398.
10. Lamoureux F et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption Cancer Res 2007 67 : 7308 7318.
11. Emery JG et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J Biol Chem 1998 273 : 14363 14367.
12. Bucay N et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 1998 12 : 1260 1268.
13. Bekker PJ et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 2004 19 : 1059 1066.
14. Kostenuik P et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases bone density in knock-in mice that express chimeric (murine/human) RANKL* J Bone Miner Res 2009 24 : 182 195.
15. Ignatoski KM et al. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model Prostate 2008 68 : 820 829.
16. Dass CR, Choong PF Zoledronic acid inhibits osteosarcoma growth in an orthotopic model Mol Cancer Ther 2007 6 : 3263 3270.
17. Zi X et al. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness Cancer Res 2005 65 : 9762 9770.
18. Takahashi N et al. Osteoblastic cells are involved in osteoclast formation Endocrinology 1988 123 : 2600 2602.
19. Akiyama T et al. In vitro and in vivo assays for osteoclast apoptosis Biol Proc Online 2005 7 : 48 59.
20. Tanaka S et al. Modulation of osteoclast function by adenovirus vector-induced epidermal growth factor receptor J Bone Miner Res 1998 13 : 1714 1720.
21. Arndt CA, Crist WM Common musculoskeletal tumors of childhood and adolescence N Engl J Med 1999 341 : 342 352.
22. Liu BY et al. Conditionally immortalized murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro Endocrinology 1998 139 : 1952 1964.
23. Hirotani H et al. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW2647 cells J Biol Chem 2004 279 : 13984 13992.
24. Raymond AK, et al. Conventional osteosarcoma. In : Fletcher CDM et al, eds. World Health Organization Classification of Tumors.
25. Ferrari S, Palmerini E Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma Curr Opin Oncol 2007 19 : 341 346.
26. Marcove RC et al. Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases J Bone Joint Surg Am 1970 52 : 411 423.
27. Chanda D et al. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis Mol Ther 2008 16 : 871 878.
28. Picci P Osteosarcoma (osteogenic sarcoma) Orphanet J Rare Dis 2007 2 : 6.
29. Cretney E et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice J Immunol 2002 168 : 1356 1361.
30. McClung MR et al. Denosumab in postmenopausal women with low bone mineral density N Engl J Med 2006 354 : 821 831.
31. Kostenuik PJ Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength Curr Opin Pharmacol 2005 5 : 618 625.
32. Miller RE et al. Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection J Immunol 2007 179 : 266 274.
33. Dougall WC et al. RANK is essential for osteoclast and lymph node development Genes Dev 1999 13 : 2412 2424.